Novel Approaches to Selective Treatments of Human Solid Tumors PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Novel Approaches to Selective Treatments of Human Solid Tumors PDF full book. Access full book title Novel Approaches to Selective Treatments of Human Solid Tumors by Youcef M. Rustum. Download full books in PDF and EPUB format.
Author: Youcef M. Rustum
Publisher: Springer Science & Business Media
ISBN: 1461524881
Category : Medical
Languages : en
Pages : 306
Get Book Here
Book Description
Author: Youcef M. Rustum
Publisher: Springer Science & Business Media
ISBN: 1461524881
Category : Medical
Languages : en
Pages : 306
Get Book Here
Book Description
Author: Shicheng Guo
Publisher: Frontiers Media SA
ISBN: 2832547095
Category : Medical
Languages : en
Pages : 124
Get Book Here
Book Description
Immune checkpoint inhibitors (ICI), such as anti-CTLA-4 and anti-PD-1/PD-L, have demonstrated significant clinical effects on the neutralization of immunosuppressive mechanisms in the tumor microenvironment (TME). Over the years, tremendous advances have been made in cancer immunotherapy, yet we are far from discovering the cure for the disease.
Author: Shivaani Kummar
Publisher: Academic Press
ISBN: 0128125705
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Novel Designs of Early Phase Trials for Cancer Therapeutics provides a comprehensive review by leaders in the field of the process of drug development, the integration of molecular profiling, the changes in early phase trial designs, and endpoints to optimally develop a new generation of cancer therapeutics. The book discusses topics such as statistical perspectives on cohort expansions, the role and application of molecular profiling and how to integrate biomarkers in early phase trials. Additionally, it discusses how to incorporate patient reported outcomes in phase one trials. This book is a valuable resource for medical oncologists, basic and translational biomedical scientists, and trainees in oncology and pharmacology who are interested in learning how to improve their research by using early phase trials. Brings a comprehensive review and recommendations for new clinical trial designs for modern cancer therapeutics Provides the reader with a better understanding on how to design and implement early phase oncology trials Presents a better and updated understanding of the process of developing new treatments for cancer, the exciting scientific advances and how they are informing drug development
Author: Stephen Neidle
Publisher: Elsevier
ISBN: 0080554954
Category : Science
Languages : en
Pages : 517
Get Book Here
Book Description
The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories
Author: Amrik Sahota
Publisher: Springer Science & Business Media
ISBN: 1461525845
Category : Medical
Languages : en
Pages : 814
Get Book Here
Book Description
These volumes record the presentations made at the VIII International Symposium on Purine and Pyrimidine Metabolism in Manheld at Indiana University, Bloomington, USA from May 22- May 27, 1994. This was a continuation of meetings held every three years with the idea of bringing clinicians and basic scientists together, which we hope results in cross-fertilization of ideas. Some of the papers presented in this volume represent oral contributions and others are from posters, but we emphasize that both are considered of equal merit. As is obvious from a perusal of the titles of the papers there has been a shift in the focus of this meeting, which reflects a general shift in the area of purine and pyrimidine metabolism. The emphasis has definitely shifted to gene structure and molecular genetics, with the beginnings we hope of gene therapy as an important branch of this area of science. Although many of the inherited diseases discussed in this text can be treated with drugs, the major thrust in the futurewill be in gene therapy, where the gene (or cDNA) will be used to treat the patient with enzyme deficiency, particularly if the patient is young. As can be seen from the Iist of authors there is a remarkable degree of international cooperation in this area across countries and continents. We thank the many participants who have attended these symposia many times, and we welcome the large group of scientists from Eastern Europe who are attending this meeting for the first time.
Author: Ann L. Jackman
Publisher: Springer Science & Business Media
ISBN: 1592597254
Category : Medical
Languages : en
Pages : 769
Get Book Here
Book Description
In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors, 5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death. The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.
Author:
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 1066
Get Book Here
Book Description
Author: Aiden Hempshall
Publisher:
ISBN:
Category :
Languages : en
Pages : 530
Get Book Here
Book Description
Author: Goran Claeson
Publisher: Springer Science & Business Media
ISBN: 1489924183
Category : Medical
Languages : en
Pages : 245
Get Book Here
Book Description
In one generation, the numerous factors involved in blood coagulation have become real protein entities, isolated in pure form, expressed by recombinant DNA techniques, and subjected to structure elucidation by the modem methods of physical chemistry, viz. , X-ray diffraction, and NMR, ESR and fluorescence spectroscopy. The major milestone in this field was the breakthrough achieved by W. Bode, R. Huber and their colleagues in 1989 in of human a-thrombin, inhibited with D-Phe-Pro-Arg determining the crystal structure chioromethyl ketone. The availability of this structure will greatly facilitate the interpretation of experiments designed to gain an understanding of the interatomic interactions between this enzyme and fibrinogen and its other substrates. At the same time, it provides a rational basis for the design and synthesis of inhibitors of thrombin, the subject of this symposium. The symposium was organized in four sessions: (1) Structural features of the interaction of thrombin with substrates and inhibitors, (2) Synthetic inhibitors, (3) Hirudin and its analogues, and (4) Pharmacological and clinical considerations. This book contains summaries of most of the papers presented, and takes its rigbful place among two others that provide a comprehensive picture of our current knowledge about thrombin, viz. the 1977 volume entitled "Chemistry and Biology of Thrombin", edited by R. L. Lundblad, J. W. Fenton II, and K. G. Mann, and the 1992 volume entitled "Thrombin: Structure and Function", edited by L. J. Berliner.
Author: S. Sideman
Publisher: Springer Science & Business Media
ISBN: 1461529468
Category : Science
Languages : en
Pages : 417
Get Book Here
Book Description
The cardiac system represents one of the most exciting challenges to human ingenuity. Critical to our survival, it consists of a tantalizing array of interacting phenomena, from ionic transport, membrane channels and receptors through cellular metabolism, energy production to fiber mechanics, microcirculation, electrical activation to the global, clinically observed, function, which is measured by pressure, volume, coronary flow, heart rate, shape changes and responds to imposed loads and pharmaceutical challenges. It is a complex interdisciplinary system requiring the joint efforts of the life sciences, the exact sciences, engineering and technology to understand and control the pathologies involved. The Henry Goldberg Workshops were set up to address these multivariable, multidisciplinary challenges. Briefly, our goals are: To encourage international cooperation and foster interdisciplinary interaction between scientists from the different areas of cardiology; to relate microscale cellular phenomena to the global, clinically manifested cardiac function; to relate conceptual modeling and quantitative analysis to experimental and clinical data; to gain an integrated view of the various interacting parameters, identify missing links, catalyze new questions, and lead to better understanding of the cardiac system. The outstanding success of past workshops has encouraged their continuation. The first Henry Goldberg Workshop, held in Haifa in 1984, introduced the concept of interaction between mechanics, electrical activation, perfusion and metabolism, emphasizing imaging in the clinical environment. The second Workshop, in 1985, discussed the same parameters with a slant towards the control aspects.
